Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 90

1.

Effect of Home-Based Exercise and Weight Loss Programs on Breast Cancer-Related Lymphedema Outcomes Among Overweight Breast Cancer Survivors: The WISER Survivor Randomized Clinical Trial.

Schmitz KH, Troxel AB, Dean LT, DeMichele A, Brown JC, Sturgeon K, Zhang Z, Evangelisti M, Spinelli B, Kallan MJ, Denlinger C, Cheville A, Winkels RM, Chodosh L, Sarwer DB.

JAMA Oncol. 2019 Aug 15. doi: 10.1001/jamaoncol.2019.2109. [Epub ahead of print]

PMID:
31415063
2.

Impact of obesity on breast cancer recurrence and minimal residual disease.

Ecker BL, Lee JY, Sterner CJ, Solomon AC, Pant DK, Shen F, Peraza J, Vaught L, Mahendra S, Belka GK, Pan TC, Schmitz KH, Chodosh LA.

Breast Cancer Res. 2019 Mar 13;21(1):41. doi: 10.1186/s13058-018-1087-7.

3.

Chronic expression of wild-type Ret receptor in the mammary gland induces luminal tumors that are sensitive to Ret inhibition.

Gattelli A, García Solá ME, Roloff TC, Cardiff RD, Kordon EC, Chodosh LA, Hynes NE.

Oncogene. 2018 Jul;37(29):4046-4054. doi: 10.1038/s41388-018-0235-y. Epub 2018 Apr 26.

PMID:
29695833
4.

WNT-Mediated Regulation of FOXO1 Constitutes a Critical Axis Maintaining Pubertal Mammary Stem Cell Homeostasis.

Sreekumar A, Toneff MJ, Toh E, Roarty K, Creighton CJ, Belka GK, Lee DK, Xu J, Chodosh LA, Richards JS, Rosen JM.

Dev Cell. 2017 Nov 20;43(4):436-448.e6. doi: 10.1016/j.devcel.2017.10.007. Epub 2017 Nov 2.

5.

The women in steady exercise research (WISER) survivor trial: The innovative transdisciplinary design of a randomized controlled trial of exercise and weight-loss interventions among breast cancer survivors with lymphedema.

Winkels RM, Sturgeon KM, Kallan MJ, Dean LT, Zhang Z, Evangelisti M, Brown JC, Sarwer DB, Troxel AB, Denlinger C, Laudermilk M, Fornash A, DeMichele A, Chodosh LA, Schmitz KH.

Contemp Clin Trials. 2017 Oct;61:63-72. doi: 10.1016/j.cct.2017.07.017. Epub 2017 Jul 21.

6.

Erratum to: Comparative clinical utility of tumor genomic testing and cell-free DNA in metastatic breast cancer.

Maxwell KN, Soucier-Ernst D, Tahirovic E, Troxel AB, Clark C, Feldman M, Colameco C, Kakrecha B, Langer M, Lieberman D, Morrissette JJD, Paul MR, Pan TC, Yee S, Shih N, Carpenter E, Chodosh LA, DeMichele A.

Breast Cancer Res Treat. 2017 Aug;164(3):639-640. doi: 10.1007/s10549-017-4339-9. No abstract available.

PMID:
28653249
7.

Comparative clinical utility of tumor genomic testing and cell-free DNA in metastatic breast cancer.

Maxwell KN, Soucier-Ernst D, Tahirovic E, Troxel AB, Clark C, Feldman M, Colameco C, Kakrecha B, Langer M, Lieberman D, Morrissette JJD, Paul MR, Pan TC, Yee S, Shih N, Carpenter E, Chodosh LA, DeMichele A.

Breast Cancer Res Treat. 2017 Aug;164(3):627-638. doi: 10.1007/s10549-017-4257-x. Epub 2017 May 12. Erratum in: Breast Cancer Res Treat. 2017 Jun 26;:.

8.

Multi-focal control of mitochondrial gene expression by oncogenic MYC provides potential therapeutic targets in cancer.

Oran AR, Adams CM, Zhang XY, Gennaro VJ, Pfeiffer HK, Mellert HS, Seidel HE, Mascioli K, Kaplan J, Gaballa MR, Shen C, Rigoutsos I, King MP, Cotney JL, Arnold JJ, Sharma SD, Martinez-Outschoorn UE, Vakoc CR, Chodosh LA, Thompson JE, Bradner JE, Cameron CE, Shadel GS, Eischen CM, McMahon SB.

Oncotarget. 2016 Nov 8;7(45):72395-72414. doi: 10.18632/oncotarget.11718.

9.

A novel approach for next-generation sequencing of circulating tumor cells.

Yee SS, Lieberman DB, Blanchard T, Rader J, Zhao J, Troxel AB, DeSloover D, Fox AJ, Daber RD, Kakrecha B, Sukhadia S, Belka GK, DeMichele AM, Chodosh LA, Morrissette JJ, Carpenter EL.

Mol Genet Genomic Med. 2016 Feb 28;4(4):395-406. doi: 10.1002/mgg3.210. eCollection 2016 Jul.

10.

Rab11-FIP1C Is a Critical Negative Regulator in ErbB2-Mediated Mammary Tumor Progression.

Boulay PL, Mitchell L, Turpin J, Huot-Marchand JÉ, Lavoie C, Sanguin-Gendreau V, Jones L, Mitra S, Livingstone JM, Campbell S, Hallett M, Mills GB, Park M, Chodosh L, Strathdee D, Norman JC, Muller WJ.

Cancer Res. 2016 May 1;76(9):2662-74. doi: 10.1158/0008-5472.CAN-15-2782. Epub 2016 Mar 1.

11.

"Braking" the Cycle of Resistance in Endocrine Therapy for Breast Cancer.

DeMichele A, Chodosh LA.

Clin Cancer Res. 2015 Nov 15;21(22):4999-5001. doi: 10.1158/1078-0432.CCR-15-1146. Epub 2015 Jul 22.

12.

Notch promotes recurrence of dormant tumor cells following HER2/neu-targeted therapy.

Abravanel DL, Belka GK, Pan TC, Pant DK, Collins MA, Sterner CJ, Chodosh LA.

J Clin Invest. 2015 Jun;125(6):2484-96. doi: 10.1172/JCI74883. Epub 2015 May 11.

13.

Tetracycline-regulated mouse models of cancer.

Yeh ES, Vernon-Grey A, Martin H, Chodosh LA.

Cold Spring Harb Protoc. 2014 Oct 1;2014(10):pdb.top069823. doi: 10.1101/pdb.top069823. Review.

PMID:
25275112
14.

Oncogene pathway activation in mammary tumors dictates FDG-PET uptake.

Alvarez JV, Belka GK, Pan TC, Chen CC, Blankemeyer E, Alavi A, Karp JS, Chodosh LA.

Cancer Res. 2014 Dec 15;74(24):7583-98. doi: 10.1158/0008-5472.CAN-14-1235. Epub 2014 Sep 19.

15.

Ceramide kinase promotes tumor cell survival and mammary tumor recurrence.

Payne AW, Pant DK, Pan TC, Chodosh LA.

Cancer Res. 2014 Nov 1;74(21):6352-63. doi: 10.1158/0008-5472.CAN-14-1292. Epub 2014 Aug 27.

16.

Akt-dependent metabolic reprogramming regulates tumor cell histone acetylation.

Lee JV, Carrer A, Shah S, Snyder NW, Wei S, Venneti S, Worth AJ, Yuan ZF, Lim HW, Liu S, Jackson E, Aiello NM, Haas NB, Rebbeck TR, Judkins A, Won KJ, Chodosh LA, Garcia BA, Stanger BZ, Feldman MD, Blair IA, Wellen KE.

Cell Metab. 2014 Aug 5;20(2):306-319. doi: 10.1016/j.cmet.2014.06.004. Epub 2014 Jul 3.

17.

SPSB1 promotes breast cancer recurrence by potentiating c-MET signaling.

Feng Y, Pan TC, Pant DK, Chakrabarti KR, Alvarez JV, Ruth JR, Chodosh LA.

Cancer Discov. 2014 Jul;4(7):790-803. doi: 10.1158/2159-8290.CD-13-0548. Epub 2014 Apr 30.

18.

Tissue phosphoproteomics with PolyMAC identifies potential therapeutic targets in a transgenic mouse model of HER2 positive breast cancer.

Searleman AC, Iliuk AB, Collier TS, Chodosh LA, Tao WA, Bose R.

Electrophoresis. 2014 Dec;35(24):3463-9. doi: 10.1002/elps.201400022. Epub 2014 Jun 12.

19.
20.

Par-4 downregulation promotes breast cancer recurrence by preventing multinucleation following targeted therapy.

Alvarez JV, Pan TC, Ruth J, Feng Y, Zhou A, Pant D, Grimley JS, Wandless TJ, Demichele A; I-SPY 1 TRIAL Investigators, Chodosh LA.

Cancer Cell. 2013 Jul 8;24(1):30-44. doi: 10.1016/j.ccr.2013.05.007. Epub 2013 Jun 13.

Supplemental Content

Loading ...
Support Center